Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer
PK and Dose Escalation and Expansion Study of DST-2970
This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation…
- Trial name
- NCT04291664
- Testing
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- DisperSol Technologies, LLC
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel.
- Trial name
- NCT02376296
- Testing
- docetaxel, Blood draws
- Where
- 20 sites in United States
- Volunteers
- 35 people
- Sponsor
- Saladax Biomedical, Inc.
Hot Flashes, Prostate Cancer
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
- Trial name
- NCT00005623
- Testing
- cyproterone acetate, quality-of-life assessment
- Where
- United States
- Sponsor
- Barr Laboratories
Prostate Cancer
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
- Trial name
- NCT06783829
- Testing
- SHR4394
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects. To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.
- Trial name
- NCT05868057
- Testing
- SHR7280 tablets, SHR7280 dry suspension
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.
- Trial name
- ANES (NCT00919022)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Bayer
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Prostate Cancer, Ovarian Cancer
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
This study investigates the safety and efficacy of Acetyl-L-Carnitine and compares it to the safety and efficacy of a placebo (inactive) tablet in the prevention of Sagopilone-induced peripheral neuropathy.
- Trial name
- NCT00751205
- Testing
- Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Prostate Cancer
Phase II, Dose Finding Study of GTx-758
The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.
- Trial name
- NCT01393119
- Testing
- GTx-758
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Metastatic Castration Resistant Prostate Cancer
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy…
- Trial name
- NCT02566772
- Testing
- TAS3681
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 130 people
- Sponsor
- Taiho Oncology, Inc.
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Prostate Cancer
Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer
RATIONALE: Ultrasound therapy kills tumor cells by heating them to several degrees above body temperature. This treatment may be effective for prostate cancer.
- Trial name
- NCT00005075
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Sponsor
- EDAP Technomed
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects…
- Trial name
- NCT00052000
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Prostate Cancer
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
- Trial name
- CAMON (NCT00919477)
- Where
- 160 sites in Japan
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms, Prostatic Neoplasms
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug.
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
- Trial name
- NCT06751329
- Testing
- DM002
- Where
- 7 sites in United States, Australia
- Volunteers
- 280 people
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Prostate Cancer
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
The purpose of this clinical research study is to assess the safety and efficacy of an investigational therapy called DCVax(TM)-Prostate.
- Trial name
- NCT00043212
- Testing
- Dendritic cell immunotherapy
- Where
- 16 sites in United States
- Sponsor
- Northwest Biotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.